Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation Frenel et al. EquipeCTCS 2023-06
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort Bringuier et al. EquipeCTCS 2022-02
Evolution of overall survival and receipt of new therapies by subtype among 20?446 metastatic breast cancer patients in the 2008-2017 ESME cohort Grinda et al. EquipeCTCS 2021-06
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis Gaillard et al. EquipeELC 2021-10-21
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer Cottu et al. EquipePC Oct 11, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients Jacquet et al. EquipeCTCS May 2018
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis Jankowski et al. EquipeELC 01 2017
Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status Bertaut et al. EquipeELC Nov 2015


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés